Fig. 3
Cross-validation of ODCs activity on patient-derived organoids. A Schematic representation of our patient-derived organoids platform. B Representative images of PDOs from PCRC-1, PCRC-2 and PCRC-3 treated with ODCLSFXR. Scale bar represents 500 µm C. Activity of all four ODCs, and corresponding monotherapies and FOLFOXIRI (folinic acid [0.5 µM], 5-FU [10 µM], SN38 [0.1 µM] and oxaliplatin [0.5 µM], red bars) in PDOs from PCRC-1 (burgundy bars), PCRC-2 (dark green bars) and PCRC-3 (navy bars). Activity is measured by ATP levels vs. CTRL (< 0.15% DMSO). Data is presented as mean of N = 3 independent experiments, error bars represent SD. Significance is determined by two-way ANOVA with *p < 0.05, **p < 0.01 and ***p < 0.001